1. INTRODUCTION {#sec1}
===============

Application of nanotechnology in drug-delivery gives a chance to deliver drugs for a delayed time with natural affinity \[[@r1]\]. Examples of nanocarriers widely employed in the field of drug delivery are dendrimers, micelles, liposomes, and nanoemulsions. These delivery systems enhance the solubility of hydrophobic compounds as well as drugs\' biodistribution and bioavailability resulting in reducing the frequency of doses, improving drug targeting, and limiting toxicity \[[@r2]\].

Among the numerous nanocarriers, Chitosan (CS) has gained more consideration because of its biocompatibility, biodegradability, mucoadhesiveness, and longer *in vivo* course time \[[@r2]-[@r4]\].

Inside the current competitive and entirely directed condition, the utilization of methodical philosophies is considered significant to enhance performance, limit error and expelling waste, for all sort of industries, just as Pharmaceutical industry. As such, Six Sigma is a standout amongst the most acknowledged arrangements of instruments for process enhancement, which intervene as Quality by Design (QbD) to the pharmaceutical business \[[@r5]\].

Execution of QbD begins with the import of Quality Target Product Profile (QTPP), Critical Quality Attributes (CQAs), Critical Process Parameters (CPPs) and Critical Material Attributes (CMAs) and associates among them, by utilizing efficient hazard-based methodologies.

In science and hazard-based methodology of QbD, the proof of mathematical models is extremely important. In QbD system, scientific models might be first standards, exact, or hybrid models. Among various approaches that generate an observational mathematical model and design space, Design of Experiment (DoE) stands out as the most productive approach. The resultant models of DoE can be utilized for screening or optimization. The expectations from the model, the number and sort of the factors are the basic corners that DoE determination relies on. In QbD structure, choice of the DoE elements can rely upon hazard appraisal or earlier information.

*Nigella sativa L*. is a well-known medicinal food plant with a long history of ethnomedicinal antimicrobial uses \[[@r6]-[@r8]\]. Its active ingredients are mainly concentrated in the essential oil of the seed \[[@r9]\]. The plant has been widely used as an analgesic, anti-inflammatory, anticancer, antimicrobial, antioxidant and gastro-protective agent \[[@r10]\]. It has been demonstrated that the therapeutic properties of *N. sativa* are due to the presence of thymoquinone, a major biologically active constituent of the essential oil \[[@r9]\], along with other high-value components such as linoleic acid, nigellone (dithymoquinone), nigilline, melanthin, and trans-anethole \[[@r11]\]. For the latter 2\~3 eras, inquiry of the anticancer action of *Nigella Sativa* oil is a relatively recent concern \[[@r12]-[@r14]\].

In spite of *Nigella Sativa* Oil (NSO) numerous profits, it has poor physical properties for instance hydrophobicity, unstable and volatile. Hence, the present work was intended to formulate chitosan-based nanoparticles containing NSO utilizing QbD approach to recognize the effects of CMAs on the CQAs of formulation and to create a design to optimize the formulation responses and screening its antimicrobial and anticancer activity.

The main purposes for developing formulations containing Essential Oils (EOs) are to shield the EO from evaporation and degradation, and to achieve a controlled release. Since the EOs exist in a liquid form at room temperature. Subsequently, the simplest form of encapsulation is to emulsify or disperse them in an aqueous solution of the carrier material.

Since CS is non-poisonous, natural, and biocompatible compound, it will pose no danger to live cells. Connecting CS's amino groups to adjacent groups like fatty acids as BA and Ci, produces derivatives which incline to dual bonds, and this feature makes it feasible for them to form nanomicelles in water capable of encapsulating fats and oils *e.g*. herbal essential oils.

2. MATERIALS AND METHODS {#sec2}
========================

2.1. Materials {#sec2.1}
--------------

Chitosan (CS; *M*w = 100,000-- 300,000 Da) with degree of deacetylation *\>*90% (Ward Hill, MA 01835, USA).  *N. sativa* oil (NSO; purity 98%) was purchased from Imtnan^®^ company, Cairo, Egypt. Benzoic Acid (BA), Cinnamic acid (Ci) were purchased from Al Nasr pharmaceutical company, Cairo, Egypt. Ethylene Dichloride (EDC) and sodium hydroxide (NaOH), Sodium Lauryl Sulfate (SLS) were purchased from El Gomheria company, Cairo, Egypt. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) was purchased from Sigma Aldrich, St. Louis, MO, USA. Human colorectal cancer cells (HC 116; ATTC ^®^ - CCL-247 ^TM^) and human prostate cancer cell line (PC3; ATCC ^®^ CRL- 1435 ^TM^) were obtained from American Type Culture Collection (ATCC, Manassas, VA, USA). Poloxamer 188, Tween 80, glacial acetic acid and methanol AR were a gift sample from Pharco company, Alex., Egypt. Any other reagent was of analytical grade and used without further purification.

2.2. Preparation of Chitosan Nanoparticles (CS-NPs) {#sec2.2}
---------------------------------------------------

Chitosan-nanoparticles were fabricated by ionic gelation technique with gentle modification \[[@r15]-[@r17]\]. Briefly, 1% acetic acid used to dissolve CS to obtain a final concentration of 1, 2, and 3% by magnetic stirrer (L32; Bibby, Staffordshire, UK) overnight, followed by filtration (0.45 μm Millipore filter). Poloxamer 188 (1%, w/v) and tween 60 were added as stabilizers to CS solution and sonication for 20 min using bath-type sonicator (Model SS101H 230, Sonix IV, CA, USA) was performed followed their addition. BA or Ci solution in EDC was added to CS solution dropwise over 20 min with a syringe under stirring to yield different ratios of CS:BA or Ci (2:1, 1:1, and 1:2). The pH of CS solution was adjusted to 4.8 using NaOH solution (2N).

*N. sativa* loaded CS-NPs were prepared using the aforementioned methodology and ratio. A fixed volume of NSO (2ml) was added to CS solution and sonicated for 5 min before the addition of BA-EDC solution. The prepared dispersions were allowed to stabilize by magnetic stirring for 30 min. CS-NPs were collected by centrifugation at 15000 rpm for 30 min at 4°C (Cooling bench centrifuge, Sigma 3-16K, Germany). The supernatant was removed by aspiration with a syringe needle and used to determine Encapsulation Efficiency (EE). The precipitate was re-dispersed in 5ml deionized water by sonication (bath sonicator, Model SS101H 230, Sonix IV, CA, USA) for 10 min \[[@r18]\].

2.3. Determination of Encapsulation Efficacy (EE) {#sec2.3}
-------------------------------------------------

The supernatant was removed by aspiration with a syringe needle and passed into separating funnel and left for 3 days for complete equilibration to estimate the amount of free oil (not encapsulated). The amount of free oil was determined by a validated spectrophotometric method established by Snehalatha *et al*. \[[@r19]\] where a calibration curve was constructed using a standard stock solution (Accurately weighed *Nigella sativa* oil (100 mg) was transferred to a 10 ml volumetric flask and dissolved and diluted to the mark with 5% SLS solution to obtain a concentration of *Nigella sativa* oil equivalent to 10 mg/ml). The calibration curve was utilized to convert the absorbance value of the free oil into an equivalent amount.

So, the encapsulated oil amount was determined by the following formula:

$\%~of~encapsulated~oil = \frac{\left( amount~of~total~oil - amount~of~free~oil \right)}{\left( amount~of~total~oil \right)} \times 100$

2.4. Implementation of QbD Tools {#sec2.4}
--------------------------------

QbD tools were employed to formulation development studies where QTPP and CQAs were created upon the clinical, pharmacokinetic (low bioavailability) and physicochemical features (strongly hydrophobic solubility) of NSO. A QTPP was well-defined (see Table **[1](#T1){ref-type="table"}**) to direct the development of chitosan nanocarrier and constructed on the QTPP, the Critical Quality Attributes (CQAs) of the drug product has been recognized (represented in Table **[2](#T2){ref-type="table"}**).

Table **1** showed the QTPP for NSO-chitosan nanoparticles whilst Table **[2](#T2){ref-type="table"}** showed the Critical Quality Attributes (CQAs) of the drug product.

### 2.4.1. Critical Material Attributes (CMAs) {#sec2.4.1}

To develop proficient nanoparticles, it has been presumed that formulation polymeric nanoparticles rely upon numerous factors, such as particle size, types of solvents and polymers used in the synthesis, area of application, *etc*. As such to decide the critical material attributes, all formulation variables have been assessed with a deeper risk evaluation offered in Table **[3](#T3){ref-type="table"}**. Additional formulation development studies were conducted according to the recognized control strategy in Table **[3](#T3){ref-type="table"}**.

### 2.4.2. Selecting Polymer Concentration and Cross Linker Types by One Factor at a Time (OFAT) {#sec2.4.2}

Before the optimization study, polymer concentration selection and selection of the crosslinker had been performed by OFAT methodology. Based on the OFAT strategy, just 5 experimental runs were found to be enough for identifying the polymer concentration and cross linker type, for the statistical optimization study. For this purpose, various formulations have been prepared, and formulation behaviors mainly particle size were estimated.

2.5. Formulation Optimization Study with Full Factorial Design {#sec2.5}
--------------------------------------------------------------

Following selection of processing parameters by OFAT studies, a randomized statistical full factorial design was performed for two independent factors for the optimization of the chitosan nanoparticles formulation; the stirring rate (A) and chitosan to benzoic acid ratio (B). STATGRAPHICS^®^ Centurion XVII Version software was used for statistical experimentation. Nine batches were prepared and evaluated for particle size (Y1), polydispersity index (Y2) and encapsulation efficacy (Y3). Mathematical equations were created for the prediction of all determined responses and a design interpretation was developed by contour plots and response surface graphics.

2.6. Physicochemical Characterization of CS-NPs {#sec2.6}
-----------------------------------------------

### 2.6.1. Particle Size (PS) and Particle Distribution (PDI) {#sec2.6.1}

Dynamic light scattering technique using Zetasizer Nano ZS. (Malvern, UK) was employed to verify the PS and PDI. Redispersion of the NPs(20µl) in 15 mL deionized water followed by 10 min sonication prior to estimation. All samples were estimated in triplicates and results were signified as mean value ± SD \[[@r18]\].

### 2.6.2. Transmission Electron Microscopy {#sec2.6.2}

Fabricated NPs morphology (plain or medicated) was resoluted by Transmission Electron Microscopy (TEM). Investigated samples were generated by suspending a small amount of NPs dispersion into deionized water (5 mL). A small amount of the developed sample was located on a paraffin pane and a grid coated with carbon was placed for 1 min to let CS-NPs stick to the carbon grid. Removal of the residual dispersion was done by adsorbing the rest with the corner of a filter paper. Samples were air dried before microscopic examination with no staining \[[@r20]\].

### 2.6.3. Scanning Electron Microscopy (SEM) of Nanoparticles {#sec2.6.3}

Samples were scattered on SEM pouch with two-fold sided sticky tape, covered with a coat of 150 Ȧ gold for 2 min by means of a SPI module TM gold sputter coater and estimated utilizing the high vacuum approach \[[@r21], [@r22]\].

2.7. *In vitro* Release Studies {#sec2.7}
-------------------------------

Dialysis technique was utilized to perform the *in vitro* release study of the optimized formula. Briefly, a Phosphate Buffered Saline (PBS) solution was used to soak and rinse the dialysis sac. NSO loaded nanoparticles resuspended in  3 mL of PBS solution were placed in the dialysis sac, hence, surrounded by 50 mL of PBS containing 5% SLS (To lessen aggregation and release oil consistently \[[@r2]\] at pH 7.4.  Time-dependent release study (from 0 to 12h) was performed. The study was performed at 37°C with 50 rpm. At definite time intervals, 3 mL of the supernatant was removed, replaced with a fresh medium of PBS containing 5% SLS at pH 7.4 and measured spectrophotometrically.

2.8. Microbiological Assay {#sec2.8}
--------------------------

The microbiological activity of NSO CS-NPs dispersion was evaluated against test microorganism (*S. aureus*; ATCC^®^ 25923). Seeded nutrient agar with the *S. aureus* was left to solidify in the petri dish. At a suitable distance, a definite amount (0.2 mg containing 0.196 mg of oil) of the dispersion and an equivalent amount of pure oil were carefully cupped into the agar layer \[[@r23]\]. The plates containing the seeded agar with the nanoparticles compared to pure oil were incubated at 37 ±0.5°C for 24h. The zone of inhibition was measured subsequently to inoculation.

2.9. *In vitro* Cytotoxicity Study {#sec2.9}
----------------------------------

The *in vitro* cytotoxicity of the encapsulated, as well as the NSO, was evaluated using the MTT assay. MTT (methyl thiazolyl-diphenyl-tetrazolium bromide) assay was conducted using two different cell lines (*i.e*. HCT 116 for colorectal carcinoma and PC3 for prostatic cancer). Results were expressed as a percentage of cell viability as compared to the control *versus* concentration. The concentration at which 50% of growth is inhibited (IC50) was determined using GraphPad prism 5.0 software (Graphpad Software, La Jolla, CA, USA). The obtained results were represented as means ± SD from at least three separate experiments. MTT assay was performed in the following manner: cells were first seeded in 96-well plates (2×10^3^ cells/well) and incubated for 24 h at 37°C in 5% CO~2~ environment. At that point, the cells were treated with NSO injection and NSO-CN-NPs, respectively, leaving the untreated cells as a control, and the cells were cultured for 24h, 48h and 72h. Then, 20 μl of MTT solution  (5 mg/ml) was added to each well and the culture was continued for 4h. The medium was then removed and 150 μl of DMSO was added per well and measured at 490 nm. The relative cell viability is estimated as follows:

$\%~relative~cell~viability = \frac{test~group~OD}{control~group~OD} \times 100\%$

3. RESULTS AND DISCUSSION {#sec3}
=========================

3.1. Preparation of CS-NPs {#sec3.1}
--------------------------

BA and Ci were selected in this study since they are considered safer than other known linkers such as glutaraldehyde and glycol which are toxic and have lots of side effects such as eye, skin and respiratory tracts irritation, headache, vomiting, fatigue and asthma \[[@r24]\].

Moreover, AitBarka *et al*. \[[@r25]\] reported that CS not only decreases the growth of pathogens but apparently it causes morphologic and structural alterations in bacteria molecules.

In the present study, CS was used in formulating CS-Ci and CS-BA nanoparticles to take advantage of the above mentioned CS's features.

3.2. Implementation of QbD Tools {#sec3.2}
--------------------------------

### 3.2.1. Determination of Critical Material Attributes (CMAs) {#sec3.2.1}

To regulate the critical material attributes, all formulation variables have been appraised with a deeper risk assessment presented in Table **[3](#T3){ref-type="table"}**. Further formulation development studies were conducted according to the identified control strategy in Table **[3](#T3){ref-type="table"}**.

### 3.2.2. Selecting Polymer Concentration and Cross Linker Types by OFAT {#sec3.2.2}

Table **[4](#T4){ref-type="table"}** showed the OFAT strategy where just 5 experimental runs were found to be enough for identification of polymer concentration and cross linker type, as a prerequisite step, for the statistical optimization study.

Three concentrations of chitosan/acetic acid solutions namely 1, 2 and 3% were investigated for particle size whereas the lower conc. of chitosan revealed smaller particle size also, the crosslinking by BA revealed smaller particle size than Ci may be explained by greater molecular weight in case of Ci.

CS concentration is possibly the most important determinant of the physicochemical characteristics of the CS-NPs. Table **[3](#T3){ref-type="table"}** showed the effect of CS concentrations on the particle size of CS-NPs. The particle size was linearly increased from 1.6±0.32 to 2.3±0.25 μm by increasing CS concentration from 1 to 3 mg/ml \[[@r26]\]. These results were also in agreement with previously published reports \[[@r27]-[@r30]\].

The increase in particle size was expected to be due to the presence of inter-molecular hydrogen bonding (due to-OH groups) and inter-molecular electrostatic repulsion (due  to-NH3^+^groups) which exist along the outline of CS \[[@r31]\].

As the CS concentration increases, a single larger particle is formed as more CS molecules tend to entangle with each other and crosslink with counter ion (BA) \[[@r30]\].

Larger particles (with high values as 2.3±0.25 μm) were obtained when the chitosan content in the matrix was increased. Moreover, narrower size distribution was obtained as the chitosan proportion is increased which was also observed for chitosan-polyglutamic acidic matrixes in the study \[[@r32]\].

The most likely explanation is that increasing the chitosan proportion in matrix reduces the gum-chitosan interactions and consequently supports the formation of particles bonded by hydrogen chitosan interactions between their chains (interchain interactions). The positive amino group of chitosan causes repulsion between the chains, leading to high nanoparticle sizes \[[@r32]\].

Regarding the choice of crosslinked fatty acid, the obtained results were in accordance with Beyki *et al*. \[[@r33]\] and revealed that bigger PS is obtained with cinnamic acid. As the cinnamic acid is a large "bulkier" polymer than benzoic acid leading to a high degree of entanglement and less efficient packing of the polymer chains, resulting in less expulsion of water from the inner structure. Effect of the concentration and molecular weight on the size of nanoparticles prepared has been previously described for chitosan--TPP nanoparticles and various other nanoparticles compositions \[[@r27], [@r34], [@r35]\].

Considering the abovementioned features of CS and BA, in the present study, CS-BA nanoparticles were synthesized by self-assembly method that led to the formation of non-polar heads inside-ward and polar heads outside-ward.

The BA and CS concentrations and ratios were determined so that 75 carboxyl groups of BA were available for each 100 amine groups of CS \[[@r36], [@r37]\]. This ratio not only led to the formation of homogeneous nanoparticles (monodisperse) with spherical morphology but also the extra available amine groups (not bound) caused the produced nanoparticles to be hydrophilic.

The monodispersity of the synthesized nanoparticles was revealed by the obtained microscopic images and the size distribution of the synthesized nanoparticles particles Fig. (**[1](#F1a){ref-type="fig"}**).

### 3.2.3. Particle Size and Size Distribution (PS and PDI) of NSO Nanoparticles {#sec3.2.3}

A particle size ranged from 361-1750 nm Fig. (**[1a](#F1a){ref-type="fig"}**) with a dispersant RI 1.4 with a viscosity (cP) equals 0.88 was considered optimum for nanoparticle formulation.

### 3.2.4. Electron Microscopy {#sec3.2.4}

SEM and TEM micrographs showed the globular (spherical) structure of the self-assembled nanoparticles with the particle size of less than 300 nm Fig. (**[1b](#F1b){ref-type="fig"}**) and **c**). The monodispersity of the synthesized nanoparticles was revealed by the microscopic images. Fig. (**[1a](#F1a){ref-type="fig"}**) revealed the size distribution of the synthesized nanoparticles \[[@r36]\]. The morphology of the selected formula of NSO-loaded chitosan nanoparticles was investigated. Vesicles diameter of \< 200 μm revealed the presence of well identified spherical nanoparticles existing in disperse pattern.

In this study, the size of the developed nanoparticles was considered satisfactorily small which was attributed to numerous intended manufacturing procedures; first, the initial sonication performed converted the long chains of CS to smaller pieces and prevented the formation of long-chained nanoparticles. Other factors that could have contributed to lowering particles size were the re-sonication and the passage of the nanoparticles through the filter.

3.3. General Full Factorial Design (Two Factors with Three Levels as Numeric Variables) {#sec3.3}
---------------------------------------------------------------------------------------

Design of experiment (DoE) using (Statgraphics XVII) ^®^ program was implemented where all factors affecting the three investigated responses were varied together. Preliminary investigations by using QbD tools were used to select the initial variables with the appropriate levels.

### 3.3.1. Factorial Experimental Design {#sec3.3.1}

Optimization of the NSO encapsulated nanoparticles was conducted using randomized general full factorial (2^3^) experimental design. Factors, responses, and targets are presented in Table **[5](#T5){ref-type="table"}**. The design investigated the effect of two independent variables at three different levels (-1, 0, and + 1, demonstrating low, medium, and high, respectively) giving up nine experimental runs (assigned F1--F9) (Table **[6](#T6){ref-type="table"}**).

The selected factors were the stirring rate (X1, a crucial factor in first emulsification) and CS/BA ratio (X2, the main backbone of nanoparticles) while the variable responses investigated were (1) particle size (Y1), (2) PDI (Y2), (3) Encapsulation Efficacy (Y3). Other formulation compositions and processing method were held constant.

The studied factors included: (A: Stirring Rate) beginning with 2000 rpm as the lowest level (-1), 4000 rpm as the highest level (+1) and 3000 rpm as center point (0). (B: CS/BA ratio, with 1:2 as the low level (-1), 2:1 as the high level (+1) and 1:1 as center point (0)). The design selected was 3-level factorial design: 3\^2 with quadratic response

Statgraphics XVII^®^ program created graphs showing the effect of the two significant variables as a surface in three-dimensional space Fig. (**[2](#F2){ref-type="fig"}**) and by interpreting the developed contour plots and surface plots, the following assumptions could be drawn: the stirring rate (variable A) was optimum at the highest level (+1) meaning that smaller particle size could be obtained by increasing the stirring rate which was in accordance with Zhu *et al.* \[[@r38]\]. Chitosan/benzoic acid molar ratio (variable B) showed the lowest Particle size and the highest encapsulation efficacy at the same level (*i.e*. the highest level (+1); *see* Fig. (**[2a](#F2){ref-type="fig"}**) and **2c**) segments A & C).StatgraphicsXVII^®^ program created a linear equation between each investigated variable and the independent levels (Stirring Rate and C/B ratio). The developed equations were created by conducting the analysis of variance and were represented in Table **[7](#T7){ref-type="table"}**. Statistically, *p*-value less than 0.05 was considered "statistically significant" for any factor studied. From statistical point of view, a significant relationship between the variables at the 95.0% confidence level is crystal clear since the *p*-values in the ANOVA analysis (in Table **[7](#T7){ref-type="table"}**) for the three investigated responses were less than 0.05.

3.4. Optimization of CS: BA Molar Ratio {#sec3.4}
---------------------------------------

One of the prime parameters to control the particle size and size distribution is CS: BA molar ratio. Therefore, a wide range of Cs: BA molar ratios (2:1 to 1:2) were assessed with constant CS concentration (1%) .The highest particle size was obtained with the lowest CS: BA molar ratio (1:2) and the particle size decreased linearly by increasing CS: BA molar ratio to 2:1 (see Fig. (**[2a](#F2){ref-type="fig"}**) segment **B**). These results were in agreement with previously published data \[[@r28]\]. Hu and co-workers reported that the higher BA concentration, the more turbid the suspension became, indicating the formation of particle agglomerates when superfluous BA connects individual nanoparticles. The reduction in the NPs zeta potential that took place as the CS: BA molar ratios increased leading to electrostatic interaction (promoting aggregate formation) between the NPs might be the proper cause for the observed increment in the particle size \[[@r39]\].

3.5. Optimizations of Stirring Speed {#sec3.5}
------------------------------------

The results obviously showed that the stirring rate had a significant impact on the particle size and polydispersity index of the resulting NPs as shown in Fig. (**[2](#F2){ref-type="fig"}**). By increasing the stirring speed from 2000 rpm to 4000 rpm, the mean particle size reduced gradually from 1780±35 nm to 341±62 nm Fig. (**[2](#F2){ref-type="fig"}**). These results were also in agreement with the previously published study \[[@r34]\] which reported the significant impact of stirring speed on the particle size and size distribution of nano-carriers. Fan and co-workers \[[@r30]\] also reported that increasing the stirring speed from 200 rpm to 800 rpm led to significant narrowing the particle size distribution. Their findings led to the suggestion that the dispersion of BA in chitosan solution could be accelerated by adequate stirring and the increased shear force helps to narrow dispersity index; however, intense stirring may destroy the repulsive force between particles causing particles aggregation. By comparing the low to the high stirring speeds, it was concluded that the moderate stirring rate improves the mixing and creates a more uniform environment for NPs formation, therefore the resulting particles exhibit narrow dispersity observed through PDI analysis which highlights a gradual decrease in the dispersity range of CS-BA-NPs from 0.9±0.04 to 0.4±0.02, when the stirring speed was increased from 2000 rpm to 4000 rpm.

3.6. Optimization of Centrifugation Conditions {#sec3.6}
----------------------------------------------

Centrifugation is one of the integral process parameter affecting the particle size, PDI and percent actual yield of the NPs \[[@r26]\]. At the centrifugation speed (15000 rpm), the NPs isolated in the supernatant and sediment had shown approximately similar mean particle size.

3.7. *In vitro* Release Study {#sec3.7}
-----------------------------

The release of the essential oil-loaded CS-BA nanoparticles at pH 7.4 was represented in Fig. (**[3](#F3){ref-type="fig"}**) and it was obvious that approximately 90% of the encapsulated NSO was released over a time period of 12 hr representing the release pattern in the bloodstream. Therefore, more oil will be absorbed into the blood system and transported *via* the blood circulatory system to the infection site more efficiently than free oil (*i.e*. oil is not encapsulated in the nanoparticles).

3.8. Microbiological Studies {#sec3.8}
----------------------------

Clear inhibition zones were obtained in optimized formulation against test organisms namely *S. aureus* represented in [Fig. (**4**)](#F4){ref-type="fig"}. Formulating NSO in nanoparticles showed uniform, even clear inhibition zone and much bigger (diameter of inhibition zone = 5.5 cm) than bare oil (diameter of inhibition zone = 3.6 cm) which is in accordance with a study conducted by Zivanovic and Chi \[[@r40]\], higher antimicrobial activity was gained in case of CS films enriched with various essential oils than CS films and free essential oils during a 5-day period.

3.9. *In vitro* Cytotoxicity Study {#sec3.9}
----------------------------------

The *in vitro* cytotoxicity of the optimized encapsulated oil formula against two different cell lines (*i.e*. HCT 116 for colorectal carcinoma and PC3 for prostatic cancer) was evaluated using MTT assay. [Fig. (**5**)](#F5){ref-type="fig"} represented the results of the conducted *in vitro* cytotoxicity study. MTT gets reduced to purple formazan by mitochondrial reductase in living cells. This reduction takes place in the presence of active reductase enzymes, and hence, this conversion is used as a measure of viable (living) cells \[[@r41], [@r42]\]. The conducted *in vitro* cytotoxicity revealed that either for free oil or encapsulated oil, there was a concentration-dependent cell viability and the encapsulated oil showed a high level of cell viability inhibition.

The IC50 of the optimized encapsulated oil formula (17.95 ±0.82 µM) was found to be 2.5 fold less than the free oil (43.56 ±1.95 µM) after 48 h of incubation in case of HCT 116 cell line and the IC50 of the optimized encapsulated oil formula (4.02 ±0.12 µM) was found to be 7 fold less than the free oil (29.72 ±1.41 µM) after 48h of incubation in case of PC3cell line as can be deducted from (Fig. **5**). The existence of different powerful anticancer components particularly thymoquinone might be responsible for the decrease in cancer cell viability. The best explanation for this behavior is the ability of the encapsulated oil to deliver the oil to individual cells, unlike the free oil which fails to reach the cells individually owing to its hydrophobicity. The observed toxicity behavior is totally attributed to the encapsulated oil since the nontoxic nature of the nanocarrier was confirmed by the high percentage of the viability of treated cells (98%). Increasing the amount of NSO is expected to have greater toxic activity and the developed nanocarrier is well suited for these kinds of drug-delivery applications. These data was declared by many patents as in the study \[[@r43]-[@r47]\].

CONCLUSION
==========

CS-BA nanoparticles were formulated using ionic gelation method and QbD tools were used to identify the optimum factors for optimization. The optimized formula formulated by chitosan to benzoic acid ratio (2:1) with stirring rate (4000 rpm) had minimum-sized particles and the highest EE (*i.e*. 341 nm and 98%). Screening of the microbiological activity conducted against *S. aureus* showed bigger and uniform inhibition zone than the bare oil (inhibition zone diameter was 5.5 cm for encapsulated oil *vs* 3.6 cm for bare oil). The *in vitro* cytotoxicity showed that the nanoparticulated oil is more efficient than the free oil in suppressing the cancer cell viability (indicated by the lower IC50 obtained for the encapsulated oil).

CURRENT & FUTURE DEVELOPMENTS
=============================

The current study utilized *in vitro* methods to investigate the potentials of encapsulated *Nigella sativa* oil. The future completion of this work will aim to conduct *in vivo* animal studies. Poor biopharmaceutical properties and stability issues had hindered the clinical benefits of nigella sativa. Nanoparticulate drug delivery systems could be one of the useful techniques in bringing forth this miraculous oil into clinical reality.
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###### Quality Target Product Profile (QTPP) for chitosan nanoparticles.

  **QTPP Element**          **Target**
  ------------------------- ----------------------------------------------------------------------
  Dosage form               Polymeric nanoparticles
  Route of administration   Oral
  Stability                 Stable at least 6-month shelf life at long term stability conditions
  Physical properties       Should have a particle size in nano range.

###### Critical Quality Attributes (CQAs) of polymeric nanoparticles.

  **CQAs**                 **Target**   **Justification of Criticality**
  ------------------------ ------------ -----------------------------------------------------------------------------------------
  Particle size            100-500 nm   In nanorange to improve permeation and bioavailability
  PDI                      0.1-0.3      Low as much as possible to reveal the mono-dispersity of the synthetized nanoparticles.
  Encapsulation efficacy   \>80%        To get much more amount of drug encapsulated in nano range

###### Risk assessment\* of Critical Material Attributes (CMAs) on drug product CQAs, with control strategies.

  ---------------------------------------------------------------------------------------------------------------
  **Drug Product**\        **Formulation Variables**                                                     
  **CQAs Assay**                                                                                         
  ------------------------ --------------------------- ------------- ----------------- ----------------- --------
  Particle size            Conc.\                      Type\         Level Range\      Level Range\      Medium
                           should be\                  should be\    should be\        should be\        
                           identified\                 identified\   identified and\   identified and\   
                           and fixed\                  and fixed\    fixed within\     fixed within\     
                           by OFAT.                    by OFAT.      DoE Design.       DoE Design.       

  PDI                      Low                         Low           Level Range\      Level Range\      Medium
                                                                     should be\        should be\        
                                                                     identified and\   identified and\   
                                                                     fixed within\     fixed within\     
                                                                     DoE Design.       DoE Design.       

  Encapsulation efficacy   Low                         Low           Level Range\      Level Range\      Low
                                                                     should be\        should be\        
                                                                     identified and\   identified and\   
                                                                     fixed within\     fixed within\     
                                                                     DoE Design.       DoE Design.       
  ---------------------------------------------------------------------------------------------------------------

***\* Relative risk ranking***: Low risk: no further investigation is needed.; Medium risk: further investigation may be needed (by literature review).; High risk: the further investigation is needed.

###### OFAT formulations and determined values for the responses.

  ----------------------------------------------------------------------------------------------------------------
  **Batch No.**   **OFAT Group**             **Type**         **Fixed**\            **Measured Response (P.S.)**
                                                              **Parameters**        
  --------------- -------------------------- ---------------- --------------------- ------------------------------
  B1\             Chitosan conc. Selection   3%\              2% NSO\               2.3 μm\
  B2\                                        2%\              Stirring rate 2000\   1.8 μm\
  B3                                         1%               Mixing time 30 min    1.6 μm

  B4\             Cross linker selection     Cinnamic acid\   2% NSO\               2.5 μm\
  B5                                         Benzoic acid     Stirring rate 2000\   1.5 μm
                                                              Mixing time 30 min    
  ----------------------------------------------------------------------------------------------------------------

###### Factors, levels, responses and targets for the full factorial design.

  **Factors**   **Levels**                                       
  ------------- ------------------------------ ---------- ------ ------
  A             Stirring rate                  2000       3000   4000
  B             Chitosan/ Benzoic acid ratio   1:2        1:1    2:1
  Responses     Target                                           
  Y1            Particle size                  Minimize          
  Y2            Polydispersity index           Minimize          
  Y3            Encapsulation efficacy         Maximize          

###### General full factorial design of experiment by (StatgraphicsXVII) ^®^ program.

  **Formulae**   **Independent Variables**   **Responses**                  
  -------------- --------------------------- --------------- ------ ------- ----
  Run            Stirring Rate               C/B             PS     PdI     EE
  Rpm            Ratio                       nm                     \%      
  1              4000.0 (+1)                 1:1 (0)         780    0.63    83
  2              4000.0 (+1)                 1:2 (-1)        1200   0.78    72
  3              2000.0 (-1)                 1:1 (0)         910    0.72    78
  4              4000.0 (+1)                 2:1 (+1)        341    0.4     98
  5              2000.0 (-1)                 1:2 (-1)        1780   0.901   63
  6              2000.0 (-1)                 2:1 (+1)        620    0.54    90
  7              3000.0 (0)                  1:1 (0)         850    0.68    80
  8              3000.0 (0)                  1:2 (-1)        1500   0.83    72
  9              3000.0 (0)                  2:1 (+1)        562    0.45    93

###### Analysis of variance.

  **Source**      **Sum of Squares**                                        **Df**   **Mean Square**   **F-Ratio**   **P-Value**
  --------------- --------------------------------------------------------- -------- ----------------- ------------- -------------
  Particle Size                                                                                                      
  Model           1.62033E6                                                 2        810164\.          46.57         0.0002
  Residual        104391\.                                                  6        17398.5                         
  Total (Corr.)   1.72472E6                                                 8        \-                              
  Equation        PS = 1443.72 - 0.164833\*Stirring Rate - 492.833\*C/B                                              
  PDI                                                                                                                
  Model           0.229974                                                  2        0.114987          287.67        0.0000
  Residual        0.0023983                                                 6        0.000399722                     
  Total (Corr.)   0.232372                                                  8        \-                              
  Equation        PDI = 0.8345 - 0.0000585\*Stirring Rate - 0.186833\*C/B                                            
  EE                                                                                                                 
  Model           993.333                                                   2        496.667           144.19        0.0000
  Residual        20.6667                                                   6        3.44444                         
  Total (Corr.)   1014.0                                                    8        \-                              
  Equation        EE = 70.0 + 0.00366667\*Stirring Rate + 12.3333\*C/B                                               
